Beyond Amyloid and Tau: Researchers Uncover Three-Dimensional Genome Disruption in Alzheimer’s Brain Cells

In a significant departure from decades of conventional neuroscientific focus, a multi-institutional research team has identified a previously underexplored dimension of Alzheimer’s disease pathology. Published in the journal Science, the study reveals that the three-dimensional (3D) spatial organization of the human genome is fundamentally altered in specific brain cells affected by Alzheimer’s. By bridging single-cell transcriptomics, spatial mapping of intact brain tissue, and advanced artificial intelligence, researchers from Carnegie Mellon University (CMU), the University of Pittsburgh School of Medicine, and the University of Washington have established higher-order chromatin structural changes as a critical component of the neurodegenerative disease.

For generations, the scientific consensus surrounding Alzheimer’s disease has been anchored primarily on two pathological hallmarks: the extracellular accumulation of amyloid-beta plaques and the intracellular aggregation of hyperphosphorylated tau tangles. While these features remain undisputed centerpieces of the disease, therapeutic strategies targeting solely amyloid and tau have yielded mixed clinical outcomes. The new findings suggest that the physical architecture of DNA within the nucleus—the way the genome folds, interacts, and establishes active versus inactive compartments—represents an entirely new layer of molecular pathology. This discovery opens critical avenues for novel therapeutic interventions aimed at modifying chromatin organization rather than simply clearing protein deposits.

The Chronology and Collaborative Scope of the Investigation

The breakthrough was made possible by converging advancements in high-throughput genomics, spatial biology, and machine learning, disciplines that have matured significantly over the past decade. The collaborative project brought together computational biologists from CMU’s Ray and Stephanie Lane Computational Biology Department, neurobiologists from the University of Pittsburgh, and specialists from partner institutions including the Broad Institute of MIT and Harvard, the University of California, Los Angeles, the University of Washington, and the Rush Alzheimer’s Disease Center.

The research team examined postmortem brain tissue samples obtained from the prefrontal cortex—a critical region at the front of the brain responsible for higher-order cognitive functions, decision-making, and memory. These samples were meticulously sourced from individuals with and without a clinical diagnosis of Alzheimer’s disease who had enrolled in long-term longitudinal dementia studies and generously donated their brains for research upon death.

To analyze these tissues, the team utilized GAGE-seq, a cutting-edge experimental technique capable of simultaneously measuring gene expression and three-dimensional genome contacts within the exact same individual cell. This single-cell resolution was then integrated with spatial transcriptomic mapping, a technology that preserves the precise physical coordinates of gene activity within intact architecture of the brain tissue. By pairing these datasets, the researchers did not merely catalog molecular abnormalities; they mapped how structural anomalies in the genome correspond directly to localized cellular dysfunction within the surrounding microenvironment.

Decoding the Folded Genome via Artificial Intelligence

One of the most innovative aspects of the study was the development and deployment of an artificial intelligence model known as Hicformer. Engineered specifically by the research team to investigate the complex relationship between genome architecture and cellular behavior, Hicformer integrates raw DNA sequence data with broad patterns of genome folding and high-resolution contact maps that chart where distant sections of chromatin physically touch.

Using these multifaceted inputs, Hicformer successfully predicts gene activity across diverse populations of brain cells. Xinyue Lu, a doctoral student in Computational Biology and co-lead of the research, described the AI model as a robust computational test bed. The tool allows scientists to simulate and explore how structural disruptions in chromosome folding propagate downstream to alter gene expression profiles.

Yang Zhang, a project scientist in the Computational Biology Department who co-led the study, emphasized the precision afforded by this approach. By measuring gene activity and genome folding within the same cell, the team bypassed the limitations of traditional bulk tissue analysis, revealing a consistent, reproducible signature of 3D genome reorganization across several distinct types of brain cells affected by Alzheimer’s.

Unraveling Structural Disruption: The Breakdown of Genomic Compartments

In a healthy human cell, DNA does not float as a disorganized, linear strand; rather, it folds into a highly organized, intricate three-dimensional architecture. This physical conformation dictates which segments of the genome are accessible to cellular machinery and, consequently, which genes are expressed. Large sections of the genome are systematically segregated into distinct active compartments (where genes are actively transcribed) and inactive compartments (where genes are silenced).

In the brains of individuals with Alzheimer’s disease, however, this orderly compartmentalization breaks down. The researchers observed that the boundaries defining active and inactive regions become increasingly blurred—a phenomenon they term "increased compartment mingling."

Furthermore, the physical interactions within the nucleus shift significantly. Several types of brain cells in Alzheimer’s tissue exhibited a reduction in local contacts between nearby sections of the genome, accompanied by an abnormal surge in long-range contacts between regions located far apart on the chromosome. Cells exhibiting high levels of compartment mingling consistently displayed lower overall levels of gene activity.

At the microscopic level, the team also detected weakened interactions between specific genes and the proximal regulatory elements—such as enhancers and promoters—that normally govern whether those genes are switched on or off. Concurrently, intermediate-distance contacts grew abnormally strong. These structural deviations correlated directly with the downregulation of gene programs essential for normal neuronal and synaptic function, while simultaneously triggering pathways associated with abnormal metabolism and cellular stress responses.

Crucially, the researchers observed striking structural abnormalities in microglia, the primary resident immune cells of the central nervous system. In Alzheimer’s disease, microglia play pivotal, complex roles in neuroinflammation and the clearance of cellular debris. The genomic reorganization identified in this study was closely linked to senescence-related programs in these immune cells, suggesting that higher-order chromatin shifts may drive the chronic neuroinflammatory states characteristic of the disease.

Expert Perspectives and the Broader Implications for Treatment

The implications of these findings extend far beyond academic pathology, offering a fresh conceptual framework for an affliction that currently affects an estimated seven million Americans—a demographic burden projected to escalate sharply in the coming decades as the global population ages.

"Alzheimer’s disease cannot be understood one layer at a time," stated Jian Ma, the Ray and Stephanie Lane Professor of Computational Biology at CMU, who led and supervised the research. "The genome’s 3D structure is a fundamental regulatory layer that helps to connect DNA sequence to gene activity. By integrating genome folding, cell state, and tissue context, we can move beyond cataloging disease-associated changes toward understanding how they fit together and which mechanisms to test next."

Echoing this sentiment, Hansruedi Mathys, assistant professor of neurobiology at the University of Pittsburgh School of Medicine, who directed the Pitt arm of the study, highlighted the transformative nature of the discovery. "We know the classic hallmarks of Alzheimer’s disease—accumulation of amyloid-beta plaques and tau tangles—but our results establish higher-order chromatin alterations as a component of the molecular pathology associated with the disease," Mathys noted.

The identification of 3D genome reorganization as a primary driver or concomitant factor in Alzheimer’s pathology reshapes the target landscape for pharmaceutical development. While traditional drug discovery has concentrated on neutralizing protein misfolding and aggregation, future therapeutic pipelines may look upstream to the nuclear architecture itself.

Roadmap for Future Research

The completion of this study establishes a rigorous foundation for subsequent investigations. With the framework provided by GAGE-seq and the Hicformer AI model, researchers are now equipped to answer pivotal causal questions that remain open in the field.

Immediate future studies will aim to determine whether specific structural modifications in chromatin actively drive the progression of cognitive decline or whether they represent secondary consequences of neurodegeneration. Furthermore, investigators will evaluate whether the newly mapped regulatory regions and disrupted genomic boundaries can be chemically targeted using epigenetic modulators or other precision medicine tools.

Supported by funding grants from the National Institutes of Health (NIH), the collaborative team included an extensive roster of contributing scientists, including CMU doctoral students Shahul Alam and Shike Wang, postdoctoral research associate Junjie Tang, Pitt doctoral students Alexander K. Kunisky and Jude Baroudi, post-baccalaureate research fellows Sahar and Sahel Ghorbanikalateh, visiting scholar Shihan Wang, alongside investigators from the Broad Institute, UCLA, the University of Washington, and the Rush Alzheimer’s Disease Center.

As the scientific community digests these findings, the paradigm of Alzheimer’s research widens. By looking past the visible wreckage of plaques and tangles deep into the coiled architecture of the cell nucleus, researchers have uncovered a new frontier in the quest to decode, treat, and ultimately conquer neurodegenerative disease.